Affiliation: Bristol-Myers Squibb
- A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infectionDavid Gardiner
Bristol Myers Squibb, Pennington, New Jersey, USA
PLoS ONE 8:e63818. 2013..Further investigation of PD-1 pathway blockade in chronic viral disease is warranted...
- A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infectionsPeter Matthews
Department of Family Medicine, Department of Health, Mpumalanga, Middelburg, 1050, South Africa
BMC Infect Dis 12:297. 2012..Complicated skin and skin structure infections (cSSSIs) frequently result in hospitalization with significant morbidity and mortality...
- Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacinJulio A Ramirez
University of Louisville, Louisville, KY 40202, USA
BMC Infect Dis 12:159. 2012..This analysis compares switch therapy using tigecycline versus levofloxacin in hospitalized patients with community-acquired pneumonia (CAP)...
- Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevirFiona McPhee
Research and Development, Bristol Myers Squibb, Wallingford, CT, USA
Hepatology 58:902-11. 2013..NS5A resistance variants persisted while NS3 resistance variants generally decayed, suggesting a higher relative fitness of NS5A variants...